PI
KPTI icon

PEAK6 Investments’s Karyopharm Therapeutics KPTI Stock Holding History

PEAK6 Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-303
Closed -$6.1K – 4538
2023
Q3 		$6.1K Hold
303
– – ﹤0.01% 3844
2023
Q2 		$8.15K Sell
303
-697
-70% -$30K ﹤0.01% 3658
2023
Q1 		$58.4K Buy
+1,000
New +$49.4K ﹤0.01% 3708
2022
Q3 		– Sell
-303
Closed -$8.15K – 5566
2022
Q2 		$8.15K Buy
+303
New +$27.8K ﹤0.01% 5846

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PEAK6 Investments's KPTI Position: Q4 2023 in Review

PEAK6 Investments sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 303 shares — an estimated $6.1K sold.

PEAK6 Investments first reported a position in KPTI in Q2 2022 and held it in 4 quarters. The position peaked at $58.4K in Q1 2023. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • PEAK6 Investments reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
  • PEAK6 Investments sold 303 Karyopharm Therapeutics shares in Q4 2023, an estimated $6.1K.
  • PEAK6 Investments first reported a position in Karyopharm Therapeutics in Q2 2022 and held it in 4 quarters.
  • PEAK6 Investments's Karyopharm Therapeutics position peaked at $58.4K in Q1 2023.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on PEAK6 Investments's 13F filing for Q4 2023, filed 13 Feb 2024.